Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of 24-hour subcutaneous ABBV-951 infusion in Parkinson's disease
NL-OMON52546Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of foscarbidopa in Parkinson's disease (PD), sponsored by AbbVie Inc. Primary endpoints: Percentage of subjects with adverse events and serious adverse events, Percentage of subjects with adverse events of special interest and 4 more. Started Dec 2020; status: active, not recruiting.
02
Drugs
foscarbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON52546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52546.